AstraZeneca across Metabolic: the full competitive set, and the 1 AXLRx report mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.